×
About 508 results

ALLMedicine™ Schizophreniform Disorder Center

Research & Reviews  144 results

What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum ...
https://doi.org/10.1007/s40272-023-00558-x
Paediatric Drugs; Baeza I, Fortea A et. al.

Jan 21st, 2023 - Long-acting injectable antipsychotics (LAIAs) are an efficacious and well-tolerated treatment in adults with schizophrenia spectrum disorders (SSD). However, there is less evidence for their use in children and adolescents. The aim of this systema...

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
https://clinicaltrials.gov/ct2/show/NCT05658510

Dec 21st, 2022 - This is a randomized, double-blind, placebo-controlled, 2-Part, Phase III study to assess the efficacy, safety, and tolerability of a 60 mcg dose of BXCL501 in adult (18-75 years old) males and females with agitation episodes associated with a pri...

Relapse, cognitive reserve, and their relationship with cognition in first episode schi...
https://doi.org/10.1016/j.euroneuro.2022.11.011
European Neuropsychopharmacology : the Journal of the Eur... Sánchez-Torres AM, Amoretti S et. al.

Dec 11th, 2022 - Schizophrenia is frequently characterized by the presence of multiple relapses. Cognitive impairments are core features of schizophrenia. Cognitive reserve (CR) is the ability of the brain to compensate for damage caused by pathologies such as psy...

Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia
https://clinicaltrials.gov/ct2/show/NCT04010305

Sep 19th, 2022 - This is a two-stage adaptive Phase Ib trial design. It is a randomized, double-blind, placebo-controlled, multiple ascending dose study assessing efficacy, pharmacokinetics, safety and tolerability of BXCL501 dosing in adult (18-65 years old) male...

Evaluation of major treatment failure in patients with recent-onset schizophrenia or sc...
https://doi.org/10.1016/j.schres.2022.07.015
Schizophrenia Research; Alphs L, Baker P et. al.

Aug 9th, 2022 - A post hoc analysis of the Disease Recovery Evaluation and Modification (DREaM) study was conducted to evaluate time to first major treatment failure (ie, arrest/incarceration or psychiatric hospitalization) in participants with recent-onset schiz...

see more →

Clinicaltrials.gov  39 results

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
https://clinicaltrials.gov/ct2/show/NCT05658510

Dec 21st, 2022 - This is a randomized, double-blind, placebo-controlled, 2-Part, Phase III study to assess the efficacy, safety, and tolerability of a 60 mcg dose of BXCL501 in adult (18-75 years old) males and females with agitation episodes associated with a pri...

Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia
https://clinicaltrials.gov/ct2/show/NCT04010305

Sep 19th, 2022 - This is a two-stage adaptive Phase Ib trial design. It is a randomized, double-blind, placebo-controlled, multiple ascending dose study assessing efficacy, pharmacokinetics, safety and tolerability of BXCL501 dosing in adult (18-65 years old) male...

A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia
https://clinicaltrials.gov/ct2/show/NCT04457310

Aug 9th, 2022 - This study proposes to examine the effects of CVL-562 (PF-06412562), a dopamine-1 receptor partial agonist, on the neural signal of brain regions involved in cognition in patients with schizophrenia and related psychotic disorders. The primary obj...

Assessing the Effectiveness of Psychiatric Interventions on the Inpatient Unit
https://clinicaltrials.gov/ct2/show/NCT03626142

May 6th, 2022 - Once patients have been discharged from hospital they will be contacted weekly for 4 weeks and then every 2 weeks until 6 months post-intervention in order to monitor their symptoms. Participants will be followed up until the end of the study (6 m...

Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
https://clinicaltrials.gov/ct2/show/NCT03201757

Feb 11th, 2022 - This study will evaluate the long-term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder

see more →

News  18 results

New Combination Med for Severe Mental Illness Tied to Less Weight Gain
https://www.medscape.com/viewarticle/972393

Apr 19th, 2022 - Olanzapine plus samidorphan (Lybalvi) vs olanzapine alone is associated with less weight gain while achieving similar clinical outcomes in patients with recent-onset severe mental illness, new research suggests. However, least one expert says the ...

Novel Drug Offers Rapid Relief From Agitation in Serious Mental Illness
https://www.medscape.com/viewarticle/950613

May 5th, 2021 - An investigational, orally dissolving film formulation of dexmedetomidine (BXCL501, BioXcel Therapeutics) may offer rapid relief from acute agitation related to schizophrenia or bipolar disorder (BD), results of two phase 3, randomized, placebo-co...

Schizophrenia in Youth Not a Neurodegenerative Illness
https://www.medscape.com/viewarticle/903516

Oct 16th, 2018 - Young patients with recent-onset schizophrenia do not show signs of cognitive deterioration or disruption of ongoing brain development in the first years following illness onset, new research shows. Results of a large longitudinal study show that ...

Schizophrenia: Recognition and Management in the ED
https://www.mdedge.com/jcomjournal/article/176657/mental-health/schizophrenia-recognition-and-management-ed
Aryeh Dienstag, MD

Oct 8th, 2018 - Schizophrenia has a heterogeneous presentation including both positive and negative symptoms. It is a relatively common disorder, affecting 0.

No Gain with Antipsych Meds Switch in Schizophrenia
https://www.medpagetoday.com/psychiatry/schizophrenia/74554

Aug 13th, 2018 - A sequential administration of amisulpride (Solian) and clozapine (Clozaril) helped achieve remission of first-episode schizophrenia symptoms, researchers reported. In a three-phase switching study, over half of individuals with their first episod...

see more →

Patient Education  2 results see all →